Targeting the Immune Privilege of Tumor-Initiating Cells to Enhance Cancer Immunotherapy
Chen Yang,Haigang Geng,Xupeng Yang,Shuyi Ji,Zhicheng Liu,Hao Feng,Qian Li,Tangansu Zhang,Sisi Zhang,Xuhui Ma,Chuchen Zhu,Nuo Xu,Yuhan Xia,Yan Li,Hongye Wang,Chune Yu,Shangce Du,Beiping Miao,Lei Xu,Hui Wang,Ying Cao,Botai Li,Lili Zhu,Xiangyu Tang,Haoyu Zhang,Chunchao Zhu,Zhao Huang,Chao Leng,Haiyan Hu,Xiaoping Chen,Shengxian Yuan,Guangzhi Jin,René Bernards,Chong Sun,Quan Zheng,Wenxin Qin,Qiang Gao,Cun Wang
DOI: https://doi.org/10.1016/j.ccell.2024.10.008
IF: 50.3
2024-01-01
Cancer Cell
Abstract:Tumor-initiating cells (TICs) possess the ability to evade anti-tumor immunity, potentially explaining many failures of cancer immunotherapy. Here, we identify CD49f as a prominent marker for discerning TICs in hepatocellular carcinoma (HCC), outperforming other commonly used TIC markers. CD49f-high TICs specifically recruit tumor-promoting neutrophils via the CXCL2-CXCR2 axis and create an immunosuppressive milieu in the tumor microenvironment (TME). Reciprocally, the neutrophils reprogram nearby tumor cells toward a TIC phenotype via secreting CCL4. These cells can evade CD8+ T cell-mediated killing through CCL4/STAT3-induced and CD49f-stabilized CD155 expression. Notably, while aberrant CD155 expression contributes to immune suppression, it also represents a TIC-specific vulnerability. We demonstrate that either CD155 deletion or antibody blockade significantly enhances sensitivity to anti-PD-1 therapy in preclinical HCC models. Our findings reveal a new mechanism of tumor immune evasion and provide a rationale for combining CD155 blockade with anti-PD-1/PD-L1 therapy in HCC.